Valuation
INMDInmode Ltd
StockNasdaqİsrailHealth careEU retail: available
9/10
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | INMD | Sector median | vs median |
|---|---|---|---|
| P/E | 9,6 | 15,6 · n=8 | %38 below |
| P/B | 1,3 | 2,3 · n=14 | %43 below |
| P/S | 2,4 | 3,5 · n=11 | %30 below |
| EV/EBIT | 6,1 | 16,9 · n=7 | %64 below |
| Free-cash-flow yield | %9,3 | %5,0 · n=12 | %88 above |
| Dividend yield | %0,00 | %1,67 · n=58 | %100 below |
| Return on equity | %13,5 | %2,5 · n=14 | %447 above |
| Return on invested capital | %15,6 | %4,6 · n=11 | %239 above |
| Gross margin | %78,5 | %66,3 · n=8 | %18 above |
| Net debt / EBITDA | −4,49 | — | — |
Value factor: 98 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| NVSNovartis AG | 20,0 | 6,1 | 16,9 | %6,3 | %3,2 | 10/10 |
| SNYSanofi | 11,1 | 1,2 | 15,3 | %8,3 | %6,1 | 7/10 |
| ALCAlcon | 31,8 | 1,4 | 25,2 | %5,6 | %0,6 | 5/10 |
| BNTXBioNTech SE | — | 1,0 | — | %1,4 | %0,0 | —/10 |
| STESTERIS | 26,3 | 2,9 | 19,8 | %4,4 | %0,9 | 7/10 |
| ICLRICON plc | 307,9 | 1,4 | 56,6 | %6,8 | %0,0 | 3/10 |
| CRSPCRISPR Therapeutics AG | — | 2,8 | — | −%7,6 | %0,0 | 1/10 |
| ABCLAbCellera Biologics | — | 4,2 | — | −%3,2 | %0,0 | 1/10 |
| ZLABZai Lab Ltd | — | 4,2 | — | −%5,5 | %0,0 | 1/10 |
| AUPHAurinia Pharmaceuticals | 7,0 | 3,6 | — | — | %0,0 | —/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Ara 2025 · filed 10 Şub 2026
Buradan sözleşmeden çıkın · AB tüketicileri: Bir satın alma işlemini iptal etmek için 14 gün.